DOCSLIB.ORG

Weekly Epidemiological Record Relevé Épidémiologique Hebdomadaire

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Weekly Epidemiological Record Relevé Épidémiologique Hebdomadaire 2010, 85, 365–372 No. 38 Weekly epidemiological record Relevé épidémiologique hebdomadaire 17 SEPTEMBER 2010, 85th YEAR / 17 SEPTEMBRE 2010, 85e ANNÉE No. 38, 2010, 85, 365–372 http://www.who.int/wer Contents Global programme Programme mondial pour 365 Global programme to eliminate lymphatic fi lariasis to eliminate lymphatic l’élimination de la fi lariose fi lariasis lymphatique Sommaire Progress report on mass drug Rapport sur l’administration de masse 365 Programme mondial pour administration in 2009 de médicaments en 2009 l’élimination de la fi lariose The Global Programme to Eliminate Lym- Le Programme mondial pour l’élimination de lymphatique phatic Filariasis is a rapidly growing la fi lariose lymphatique, lancé en 2000 avec global public health programme which pour but d’éliminer la fi lariose lymphatique was launched in 2000 with the goal to en tant que problème de santé publique d’ici eliminate lymphatic fi lariasis as a public- 2020, est un programme mondial qui continue health problem by 2020. This report sum- à prendre de l’ampleur le plus rapidement. Ce marizes the progress made in mass drug rapport fait le point sur les progrès réalisés en administration (MDA) in 2009. During this 2009 en matière d’administration de masse de time, lymphatic fi lariasis was endemic in médicaments (AMM). Au cours de cette 81 countries: 68 of these countries had période, la fi lariose est restée endémique dans completed the mapping of endemic foci by 81 pays: 68 d’entre eux ont achevé la cartogra- the end of 2009; mapping is in progress in phie de leurs foyers d’endémie à la fi n 2009; 11 countries; and only 2 countries have yet 11 ont progressé dans l’établissement de celle- to start mapping. Of the endemic coun- ci; et 2 seulement ne l’ont pas encore abordée. tries, MDA was not required in 10. MDA Parmi les pays d’endémie, 10 n’ont pas eu has been implemented in 53 countries; besoin d’une AMM. Celle-ci a été mise en 18 countries – mainly in the WHO African œuvre dans 53 pays; 18 – situés principale- Region – have not yet started delivery of ment dans la Région africaine de l’OMS – n’ont MDA. Of the 37 endemic countries outside pas encore commencé à l’appliquer. Sur les the African Region that require MDA, 37 pays d’endémie situés en dehors de la 34 countries have implemented it; only Région africaine de l’OMS et qui nécessitent New Caledonia, Palau and Sudan have not une AMM, 34 l’ont déjà mise en œuvre; seuls initiated MDA. la Nouvelle-Calédonie, les Palaos et le Soudan n’ont pas encore entrepris cette administra- tion de masse. In 2009, the programme targeted 496 mil- Sur les 496 millions de personnes ciblées par lion people to receive MDA, and treated le Programme en 2009 pour une AMM, 385 385 million; thus, reported treatment cov- millions ont été traitées; ainsi, la couverture erage was 77.7%. The number of people rapportée pour le traitement a été de 77,7%. treated was about 100 million fewer than Le nombre de personnes traitées a été infé- in 2008. All of the WHO regions, except the rieur d’environ 100 millions à celui de 2008. Eastern Mediterranean and South-East Toutes les Régions de l’OMS, à l’exception de Asia Regions, treated more people in 2009 celles de la Méditerranée orientale et de l’Asie than in 2008. In the Eastern Mediterranean du Sud-Est, ont traité davantage de gens en 2009 Region, Egypt did not implement MDA in qu’en 2008. Dans la Région de la Méditerranée WORLD HEALTH ORGANIZATION 2009. In the South-East Asia Region, orientale, l’Égypte n’a pas appliqué l’AMM en Geneva 125 million fewer people were treated than 2009. Dans la Région de l’Asie du Sud-Est, in 2008. In 2009 people in all endemic 125 millions de personnes de moins ont été trai- ORGANISATION MONDIALE DE LA SANTÉ countries except Brazil received combina- tées qu’en 2008. En 2009, les habitants de tous Genève tion therapy comprising diethylcarbamaz- les pays d’endémie sauf le Brésil ont reçu une ine (DEC) plus albendazole, or ivermectin association thérapeutique comprenant de la Annual subscription / Abonnement annuel plus albendazole. diéthylcarbamazine (DEC) plus de l’albendazole, Sw. fr. / Fr. s. 346.– ou de l’ivermectine plus de l’albendazole. 06.2010 ISSN 0049-8114 Data on the impact of treatment from sen- Les données relatives aux effets du traitement Printed in Switzerland tinel sites and spot-check sites suggest en provenance des sites sentinelles et des sites 365 that delivering 5–6 rounds of MDA reduces the preva- de vérifi cation ponctuelle laissent à penser que le fait de procé- lence of microfi laraemia in many provinces in many der à 5 ou 6 campagnes d’AMM permet de réduire la prévalence endemic countries. The public-health benefi ts gained de la microfi larémie dans beaucoup de provinces des pays d’en- from falling prevalence rates are signifi cant: analyses démie. Les avantages tirés de la chute des taux de prévalence revealed that MDA averted 32 million disability-adjusted sur le plan de la santé publique sont importants: des analyses life years, and an estimated 6.6 million neonates were ont révélé que l’AMM avait permis de prévenir 32 millions d’an- protected from clinical disease. The disability-manage- nées de vie ajustées sur l’incapacité et que, selon les estimations, ment programme is being implemented in 27 coun- 6,6 millions de nouveau-nés étaient ainsi protégés contre la tries. forme clinique de la maladie. Le programme de prise en charge des incapacités est mis en œuvre dans 27 pays. Map 1 shows the countries where lymphatic fi lariasis La Carte 1 montre les pays dans lesquels la fi lariose lymphati- was endemic in 2009 and the status of mass drug ad- que était endémique en 2009 et la situation de l’AMM dans ces ministration in those countries. pays. Table 1 provides details of the number of implementa- Le Tableau 1 fournit des indications sur le nombre d’unités de tion units included in MDA programmes, the population mise en œuvre fi gurant dans les programmes d’AMM, la popu- covered by an implementation unit, and the number of lation couverte par unité et le nombre de personnes traitées people treated in different countries. Table 2 includes dans différents pays. Le Tableau 2 renferme des données rela- data on MDA in different WHO regions or regional pro- tives à l’AMM dans différentes Régions de l’OMS ou groupes gramme review groups. Table 3 shows the estimated d’examen des programmes régionaux. Le Tableau 3 montre le number of preschool-aged children and school-aged nombre estimé d’enfants d’âge préscolaire et scolaire traités par children treated by MDA in 2009. l’AMM en 2009. Fig. 1 shows the proportion of the at-risk population La Fig. 1 montre la proportion de la population à risque rece- receiving single-drug treatment or combination drug vant une monothérapie ou un traitement associé. La Fig. 2 treatment. Fig. 2 presents the proportion of the at-risk présente la proportion de la population à risque couverte par population covered by MDA by WHO region or regional l’AMM, par Région de l’OMS ou par groupe d’examen du programme review group. Fig. 3 presents the number programme régional. La Fig. 3 indique le nombre de pays of countries implementing MDA and the number of mettant en œuvre l’AMM et le nombre de personnes traitées people treated with either single-drug therapy or 2-drug par mono- ou bithérapie. combination therapy. African Region Région africaine Lymphatic fi lariasis is endemic in 39 of the 46 Member La fi lariose lymphatique est endémique dans 39 des 46 États States in the Region. Of these, 27 have completed map- Membres de la Région. Parmi eux, 27 ont achevé la cartographie Map 1 Countries where lymphatic fi lariasis is endemic and status of mass drug administration (MDA) in those countries, 2009 Carte 1 Pays dans lesquels la fi lariose lymphatique est endémique et situation de l’administration de masse de médicaments (AMM) dans ces pays, 2009 Federated States Trinidad and Cape Verde – of Micronesia – Tobago – Cap-Vert Etats fédérés Trinité-et- Palau – de Micronésie Tobago Palaos Tuvalu Wallis and Kiribati Futuna – Sri Lanka Wallis et Seychelles Marshall Islands – Futuna Iles Marshall Cook Islands – Sao Tome Maldives Iles Cook and Principe – Vanuatu Sao Tomé- Comoros – Comores Samoa French Polynesia – et-Principe Solomon Islands – Polynésie française Iles Salomon – Niue – Nioué Mauritius – Fiji New Fidji American Maurice Caledonia – Samoa – Tonga Nouvelle- Samoa Calédonie américaines Endemic countries implementing MDA. – Pays d’endémie mettant en place l’AMM. Countries unlikely to require MDA. – Pays où il est peu probable qu’une AMM soit requise. Endemic countries and territories. – Pays et territoires d’endémie. Endemic countries where the target was achieved and the MDA stopped. – Pays d’endémie où l’objectif a été atteint et l’AMM a été arrêtée. 366 WEEKLY EPIDEMIOLOGICAL RECORD, NO. 38, 17 SEPTEMBER 2010 Table 1 Mass drug administration (MDA) for lymphatic fi lariasis by WHO region or regional programme review group, 2009 Tableau 1 Administration de masse de médicaments (AMM) contre la fi lariose lymphatique par Région OMS ou par groupe d’examen du programme régional, 2009 Total popula- Drug used WHO region or tion covered during MDA No. of imple- Reported drug regional program- by implemen- Reported no. campaigns – mentation units coverage me review group tation units of people trea- Médicament delivering MDA – (%)a – Couver- – Région OMS ou Country – Pays – Population ted – Nombre employé Nombre d’unités ture médi- groupe d’examen totale cou- de personnes dans les de mise en œu- camenteuse du programme verte
Load more

Recommended publications
  • WHO Technical Consultation to Review the Role of Drugs in Malaria Prevention for People Living in Endemic Settings
    Malaria Policy Advisory Committee Meeting 13—14 May 2020, Geneva, Switzerland Background document for Session 5 WHO technical consultation to review the role of drugs in malaria prevention for people living in endemic settings Meeting report, 16–17 October 2019, Geneva, Switzerland Summary On 16–17 October 2019, the World Health Organization (WHO) convened a Technical Consultation to review the use of medicines for malaria prevention in endemic countries and to identify opportunities to increase their impact through review of the flexibility of the recommendations for their deployment. Experts reviewed the policies and use of chemoprevention as currently endorsed by WHO, including intermittent preventive treatment in pregnancy (IPTp), intermittent preventive treatment in infants (IPTi), seasonal malaria chemoprevention (SMC) and mass drug administration (MDA) for the reduction of disease burden in emergency situations. By reviewing these strategies side-by-side for the first time, the meeting was able to consider opportunities for optimization. Additional potential applications of chemoprevention were also reviewed, and key considerations identified to develop a broader role for malaria chemoprevention in malaria-endemic populations. Key conclusions of the meeting included: • There is a need for general guidance on the broader use of chemoprevention. Chemoprevention is an important approach in the package of strategies that countries may use to decrease their malaria burden and/or move towards malaria elimination. Development of broader, more flexible guidance that builds on existing chemoprevention recommendations in specific populations is expected to support the greater, more rational use of chemoprevention and enhance its impact. • Chemoprevention strategies may be tailored to country-specific needs. Guidance should be flexible enough to enable adaptation of strategies according to the needs of different countries and settings.
    [Show full text]
  • The Safety and Effectiveness of Single Dose Primaquine As a P
    Malaria Policy Advisory Committee Meeting 11-13 September 2012, WHO HQ Session 5 WHO Evidence Review Group: The Safety and Effectiveness of Single Dose Primaquine as a P. falciparum gametocytocide Pullman Hotel, Bangkok, Thailand, 13-15 August 2012 Meeting Report Background Deployed since the early 1950s primaquine is the most Glossary: widely used 8-aminoquinoline antimalarial drug. It has been used extensively in the radical treatment of P. vivax G6PD: Glucose-6-phosphate dehydrogenase and P. ovale malaria, and as a single dose G6PDd: G6PD deficient gametocytocide in falciparum malaria. The main limitation to its use has been haemolytic toxicity. The 8- AHA: Acute haemolytic anaemia aminoquinoline antimalarials produce dose dependent acute haemolytic anaemia (AHA) in individuals who have ACT: Artemisinin combination treatment G6PD deficiency, an inherited X-linked abnormality. The MDA: Mass drug administration prevalence of the underlying allelic genes for G6PD deficiency varies typically between 5 and 32.5 % in POC: Point of care malaria endemic areas of Asia and Africa. Use of primaquine as a gametocytocide has great potential to reduce the transmission of falciparum malaria in low transmission settings, and in particular to help contain the spread of artemisinin resistant falciparum malaria in SouthEast Asia. The World Health Organisation currently recommends addition of primaquine 0.75 mg base/kg (adult dose 45 mg) to treatment regimens for P. falciparum malaria in areas of low transmission, particularly in areas where artemisinin resistant falciparum malaria is a threat, “when the risk for G6PD deficiency is considered low or testing for deficiency is available”. Unfortunately there is often uncertainty about the prevalence and severity of G6PD deficiency, and testing for it is usually not available in these areas.
    [Show full text]
  • Meeting Report of the WHO Evidence Review Group on Mass Drug Administration for Malaria
    Malaria Policy Advisory Committee Meeting 10–12 April 2019, Geneva, Switzerland Background document for Session 7 Meeting report of the WHO Evidence Review Group on mass drug administration for malaria 11–13 September 2018, Geneva, Switzerland Summary Mass drug administration (MDA), the strategy of administering antimalarials to all age groups of a defined population (except those for whom the drugs are contraindicated) at the same time regardless of infection status, has recently received renewed interest for its potential to accelerate malaria elimination through rapid and sustained reduction of transmission. In 2015, the World Health Organization (WHO) recommended that the use of time-limited MDA in combination with other malaria control measures could be considered in the following scenarios: in areas approaching interruption of Plasmodium falciparum transmission; in the Greater Mekong subregion (GMS) as a component of accelerated malaria elimination efforts; and in epidemics and complex emergencies to reduce morbidity and mortality. Since WHO’s recommendation, new studies have been conducted in areas of low to moderate transmission in Africa and in the GMS, generating additional data on the role of MDA in rapidly reducing transmission. In light of the new data, WHO convened an evidence review meeting to revise and refine the current recommendations on MDA to accelerate malaria elimination, focusing on the evidence emerging from several studies in African countries and the GMS. Modelling studies and results of the update to the Cochrane Systematic Review were also presented and discussed at the meeting. This meeting report provides a summary of the evidence presented, draft conclusions and a proposed update to the WHO recommendations.
    [Show full text]
  • Understanding Adherence to Reactive Treatment of Asymptomatic Malaria
    www.nature.com/scientificreports OPEN Understanding adherence to reactive treatment of asymptomatic malaria infections in The Gambia Fatou Jaiteh1,2,3*, Joseph Okebe1,4, Yoriko Masunaga2,3, Umberto D’Alessandro1, Jane Achan1, Charlotte Gryseels2, Daniel de Vries3, Joan Muela Ribera5 & Koen Peeters Grietens2,5,6 The impact of diferent types of reactive case detection and/or treatment strategies for malaria elimination depends on high coverage and participants’ adherence. However, strategies to optimise adherence are limited, particularly for people with asymptomatic or no infections. As part of a cluster-randomized trial to evaluate the efect of reactive treatment in The Gambia, all residents in the compound of a diagnosed clinical malaria patient received dihydro-artemisinin–piperaquine (DP). Using a mixed method approach, we assessed which factors contribute to adherence among the contacts of malaria cases that showed no symptoms. Adherence was defned as the proportion of compound members that (1) returned all medicine bags empty and (2) self-reported (3-day) treatment completion. Among the 273 individuals from 14 compounds who received DP, 227 (83.1%) were available for and willing to participate in the survey; 85.3% (233/273) returned empty medicine bags and 91.6% (208/227) self-reported treatment completion. Although clinical malaria was not considered a major health problem, reported adherence was high. The drivers of adherence were the strong sense of responsibility towards protecting the individual, compound and the village. Adherence can be optimised through a transdisciplinary implementation research process of engaging communities to bridge the gap between research goals and social realities. Malaria infected but asymptomatic carriers (i.e.
    [Show full text]
  • Review of Mass Drug Administration and Primaquine
    Contents Acknowledgements ...................................................................................................................................... 2 Acronyms ...................................................................................................................................................... 3 Introduction .................................................................................................................................................. 4 Methods ....................................................................................................................................................... 4 Findings ......................................................................................................................................................... 6 Study objectives and design ............................................................................................................ 9 Contextual parameters - endemicity, seasonality, target population .......................................... 10 Outcome measures ....................................................................................................................... 13 Drug regimens ............................................................................................................................... 13 Co-Interventions ............................................................................................................................ 15 Delivery methods and community engagement ..........................................................................
    [Show full text]
  • A Guide for Independent Monitoring of Mass Drug Administration for Neglected Tropical Disease Control
    A Guide for Independent Monitoring of Mass Drug Administration for Neglected Tropical Disease Control A case study from Sierra Leone Helen Keller International Table of Contents 1.0 - Introduction ........................................................................................................................... 4 2.0 - Overview of Independent Monitoring .................................................................................... 5 3.0 - Independent Monitors ........................................................................................................... 6 3.1 - Training of the Independent Monitors ............................................................................... 6 4.0 - Sampling ............................................................................................................................... 8 4.1 - Sampling steps .................................................................................................................. 8 4.2 - Sampling of sites for in-process monitoring ...................................................................... 9 4.3 - Sampling of sites for end-process monitoring ................................................................. 10 5.0 - Interviews ............................................................................................................................ 11 5.1 - Household interviews ...................................................................................................... 11 5.2 - Community interviews ....................................................................................................
    [Show full text]
  • Mass Drug Administration, Mass Screening and Treatment and Focal Screening and Treatment for Malaria
    Malaria Policy Advisory Committee Meeting 16–18 September 2015, Geneva, Switzerland Background document for Session 1 Mass drug administration, mass screening and treatment and focal screening and treatment for malaria WHO Evidence Review Group meeting report WHO Headquarters, Geneva 20–22 April 2015 Summary Mass drug administration (MDA) has received renewed interest over the past decade in the context of malaria elimination, as part of multidrug resistance containment and (more recently) in emergency situations such as the West African Ebola outbreak. To develop WHO recommendations, a group of experts met in April 2015 to review recent evidence on the use of MDA, mass screening and treatment (MSAT) and focal screening and treatment (FSAT) in specific epidemiological settings. The following recommendations were proposed by the WHO evidence review group, for consideration by the WHO Malaria Policy Advisory Committee. Proposed recommendations 1. Use of MDA to interrupt transmission of falciparum malaria can be considered in endemic island communities and in low-endemic non-island settings approaching elimination, where there is minimal risk of re-introduction of infection, good access to treatment, and implementation of vector control and surveillance. 2. In view of the growing threat of multidrug resistance and the need to use extreme measures, MDA can be considered as a component of malaria elimination efforts in the Greater Mekong subregion, in areas with good access to treatment, vector control and good surveillance. 3. Use of MDA to rapidly reduce malaria morbidity and mortality can be consid¬ered for epidemic control as part of the immediate response, while other interventions are put in place.
    [Show full text]
  • The Challenge of Schistosomiasis Frank O Richards Jr,A Abel Eigege,B Emmanuel S Miri,B MY Jinadu,C & Donald R Hopkins A
    Integration of mass drug administration programmes in Nigeria: the challenge of schistosomiasis Frank O Richards Jr,a Abel Eigege,b Emmanuel S Miri,b MY Jinadu,c & Donald R Hopkins a Problem Annual mass drug administration (MDA) with safe oral anthelminthic drugs (praziquantel, ivermectin and albendazole) is the strategy for control of onchocerciasis, lymphatic filariasis (LF) and schistosomiasis. District health officers seek to integrate treatment activities in areas of overlapping disease endemicity, but they are faced with having to merge different programmatic guidelines. Approach We proceeded through the three stages of integrated MDA implementation: mapping the distribution of the three diseases at district level; tailoring district training and logistics based on the results of the mapping exercises; and implementing community- based annual health education and mass treatment where appropriate. During the process we identified the “know–do” gaps in the MDA guidelines for each disease that prevented successful integration of these programmes. Local setting An integrated programme launched in 1999 in Plateau and Nasarawa States in central Nigeria, where all three diseases were known to occur. Relevant changes Current guidelines allowed onchocerciasis and LF activities to be integrated, resulting in rapid mapping throughout the two states, and states-wide provision of over 9.3 million combined ivermectin–albendazole treatments for the two diseases between 2000 and 2004. In contrast, schistosomiasis activities could not be effectively integrated because of the more restrictive guidelines, resulting in less than half of the two states being mapped, and delivery of only 701 419 praziquantel treatments for schistosomiasis since 1999. Lessons learned Integration of schistosomiasis into other MDA programmes would be helped by amended guidelines leading to simpler mapping, more liberal use of praziquantel and the ability to administer praziquantel simultaneously with ivermectin and albendazole.
    [Show full text]
  • Envisage Repurposing Ivermectin for SARS-COV-2
    Am. J. Trop. Med. Hyg., 103(1), 2020, pp. 10–11 doi:10.4269/ajtmh.20-0295 Copyright © 2020 by The American Society of Tropical Medicine and Hygiene Stories from the Field Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2 Claire Njeri Wamae1,2* 1School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya; 2Kenya Medical Research Institute, Nairobi, Kenya I have spent over 40 years studying parasitic worms and the (Zithromax), among others. By 2018, up to 1.752 billion drugs we use to treat them. With this background, I suggest treatments were distributed to affected populations through- that large-scale annual mass drug administration for pre- out endemic areas in the world. As of 2015, 99% of persons ventive chemotherapy of neglected tropical diseases may be infected by Onchocerca volvulus globally were living in 31 contributing to keeping COVID-19 cases in check and below African countries (http://www.who.int/gho); thus, Africa projections in Africa. received the bulk of ivermectin donations. My fascination with worms started in 1979, while un- A casual look at the O. volvulus (http://www.who.int/gho) dertaking a food science major in college. I was dismayed to and COVID-19 (http://africacdc.org) maps lacks the typical learn of tiny blackflies that breed in fast-flowing rivers in Africa neglected tropical disease overlaps. In equatorial Africa, we and transmit river blindness! What horrified me most about the commonly find high prevalence and overlaps of the afore- strange disease was the textbook picture depicting a naked mentioned five diseases in same geographical areas (pop- blind African adult man, led on a cane by a little boy (naked ulations).
    [Show full text]
  • G6PD Deficiency in Latin America: Systematic Review on Prevalence and Variants
    Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 109(5): 553-568, August 2014 553 G6PD deficiency in Latin America: systematic review on prevalence and variants Wuelton M Monteiro1,2/+, Fernando FA Val1,2, André M Siqueira1,2, Gabriel P Franca1, Vanderson S Sampaio1,2, Gisely C Melo1,2, Anne CG Almeida1,2, Marcelo AM Brito1,2, Henry M Peixoto3, Douglas Fuller4, Quique Bassat5, Gustavo AS Romero3,6, Maria Regina F Oliveira3,6, Marcus Vinícius G Lacerda1,2 1Gerência de Malária, Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, AM, Brasil 2Escola Superior de Ciências da Saúde, Universidade do Estado do Amazonas, Manaus, AM, Brasil 3Faculdade de Medicina, Universidade de Brasília, Brasília, DF, Brasil 4Department of Geography and Regional Studies, University of Miami, Coral Gables, FL, USA 5Barcelona Centre for International Health Research, Hospital Clinic, University of Barcelona, Barcelona, Spain 6Instituto Nacional de Ciência e Tecnologia para Avaliação de Tecnologias em Saúde, Porto Alegre, RS, Brasil Plasmodium vivax radical cure requires the use of primaquine (PQ), a drug that induces haemolysis in glucose- 6-phosphate dehydrogenase deficient (G6PDd) individuals, which further hampers malaria control efforts. The aim of this work was to study the G6PDd prevalence and variants in Latin America (LA) and the Caribbean region. A sys- tematic search of the published literature was undertaken in August 2013. Bibliographies of manuscripts were also searched and additional references were identified. Low prevalence rates of G6PDd were documented in Argentina, Bolivia, Mexico, Peru and Uruguay, but studies from Curaçao, Ecuador, Jamaica, Saint Lucia, Suriname and Trini- dad, as well as some surveys carried out in areas of Brazil, Colombia and Cuba, have shown a high prevalence (> 10%) of G6PDd.
    [Show full text]
  • Lymphatic Filariasis: Elimination in the Americas
    Lymphatic Filariasis: Elimination in the Americas Center for Global Health Division of Parasitic Diseases and Malaria The Burden of Lymphatic Filariasis (LF) To date, close to 700 million people in some of the poorest areas globally have received treatment to prevent one of the world’s most incapacitating diseases, lymphatic filariasis. ymphatic filariasis (LF) is a disabling parasitic disease caused Lby microscopic worms that are spread from person-to-person by the bite of an infected mosquito. The adult worms live in the human lymphatic system and can cause lymphedema (swelling) affecting the legs, arms, or breasts. They can also cause hydrocele (severe fluid accumulation) affecting the genitalia of men. Chronic manifestations of lymphatic filariasis, which usually take place years after initial infection, can cause pain, severe and irreversible disfigurement, and stigmatization. Lymphatic filariasis is one of the world’s neglected tropical diseases (NTDs), a group of infectious diseases affecting more than 1 billion people that is responsible for tremendous suffering and economic loss. LF is recognized as one of the most disabling and economically costly NTDs, as infection with the disease can lead to lower productivity and inability to work. Over 120 million persons are infected with LF, a disease that can be eliminated In 2000, the World Health Organization launched The Global Programme to Eliminate Lymphatic Filariasis, with a target elimination date of 2020. This initiative is driven by a two-fold strategy to interrupt the spread of infection and reduce the suffering of persons already infected. These efforts to interrupt transmission and improve disease management ensure that future generations will not suffer the same disability.
    [Show full text]
  • Evaluation of Mass Drug Administration Impact on Transmission of Lymphatic Filariasis in 13 Sanitary Districts in Burkina Faso
    Journal of Cosmetics, Dermatological Sciences and Applications, 2018, 8, 185-194 http://www.scirp.org/journal/jcdsa ISSN Online: 2161-4512 ISSN Print: 2161-4105 Evaluation of Mass Drug Administration Impact on Transmission of Lymphatic Filariasis in 13 Sanitary Districts in Burkina Faso Nomtondo Amina Ouedraogo1*, Sidnoma Muriel Ouedraogo1, Gilbert Patrice Tapsoba1, W. Roland Bougma2, Mamadou Serme3, Apollinaire Kima3, Nadia Kaboret4, Ibrahim Sangare3, Clarisse Bougouma3, François Drabo3 1Research and Training Unit in Health Sciences, University Ouaga I Pr Joseph Ki-Zerbo, Ouagadougou, Burkina Faso 2Neglected Tropical Diseases National Program, Lymphatic Filariasis Unit, Ouagadougou, Burkina Faso 3Neglected Tropical Diseases National Program (NTD NP), Ouagadougou, Burkina Faso 4University Hospital of Tengandogo, Ouagadougou, Burkina Faso How to cite this paper: Ouedraogo, N.A., Abstract Ouedraogo, S.M., Tapsoba, G.P., Bougma, W.R., Serme, M., Kima, A., Kaboret, N., Introduction: Lymphatic filariasis (LF) is one of the neglected tropical dis- Sangare, I., Bougouma, C. and Drabo, F. eases targeted for elimination as a public health issue in the world by 2020. To (2018) Evaluation of Mass Drug Adminis- achieve this goal, one of the strategies is interruption of transmission using tration Impact on Transmission of Lym- phatic Filariasis in 13 Sanitary Districts in chemotherapy (mass drug administration). Burkina Faso in west Africa, an Burkina Faso. Journal of Cosmetics, Der- endemic country, has endorsed this resolution. In 2000, all Sanitary Districts matological Sciences and Applications, 8, (SD) in the country were endemic, and then a national elimination program 185-194. has made it possible to stop mass treatment in 45 out of 70 SD over 12 years.
    [Show full text]